Team CL are lacing up their running shoes

29th April 2022


With the Great Birmingham Run just round the corner, Team CL are lacing up their running shoes and getting ready to join in the race.  
 
Cure Leukaemia trustees Laura Shoef and Alston Owens will be joined by CEO James McLaughlin and Financial Controller Andrew Wilkes at the start line on Sunday 1st May 2022 at the Birmingham Great Run. All four will be taking part in the half marathon, running a total of just over 13 miles.
 
Alston Owens, trustee, said:  

“ 13.1 miles can be challenging and requires training consistency which makes it all worthwhile supporting Cure Leukaemia raise awareness! I support their mission because it's something my family has experienced first-hand-! In addition, when you donate money through fundraisers like ours, then we get to continue funding clinical trials, which will lead us toward CL to supporting many more patients that are living with this terrible disease.” 

This will also be his 3rd half marathon, but the first time he’s ever done a solid training routine.  

Laura Shoef has also done many running events beforehand, and wanted to say a big ‘thank you’ to everyone too:  

“Just a big thank you to all runners helping to raise the profile and raise funding for this great charity!”  

 

James McLaughlin, CEO, is an avid runner, and previously takes part in the ‘Tour of the TAP’, a running event that tours the country visiting all the Tap Centres that are so crucial to Cure Leukaemias work and research.  
The Tour of the TAP sees James running over 100 miles in 14 days and is the equivalent of running 4 marathons! 

 
From all of us not running at Cure Leukeamia, the best of luck to the Team Cl runners ahead of this Sundays Marathon, and we’ll see you at the finish line.

< Back to List

What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell